Your browser doesn't support javascript.
loading
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Boeree, Martin J; Heinrich, Norbert; Aarnoutse, Rob; Diacon, Andreas H; Dawson, Rodney; Rehal, Sunita; Kibiki, Gibson S; Churchyard, Gavin; Sanne, Ian; Ntinginya, Nyanda E; Minja, Lilian T; Hunt, Robert D; Charalambous, Salome; Hanekom, Madeleine; Semvua, Hadija H; Mpagama, Stellah G; Manyama, Christina; Mtafya, Bariki; Reither, Klaus; Wallis, Robert S; Venter, Amour; Narunsky, Kim; Mekota, Anka; Henne, Sonja; Colbers, Angela; van Balen, Georgette Plemper; Gillespie, Stephen H; Phillips, Patrick P J; Hoelscher, Michael.
Affiliation
  • Boeree MJ; Department of Lung Diseases, Radboud University Medical Center, Nijmegen, Netherlands. Electronic address: martin.boeree@radboudumc.nl.
  • Heinrich N; Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich, Munich, Germany; German Center for Infection Research, Partner Site Munich, Germany.
  • Aarnoutse R; Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands.
  • Diacon AH; Centre for Clinical Tuberculosis Research, Department of Science and Technology and National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, South Africa.
  • Dawson R; Centre for Tuberculosis Research Innovation, University of Cape Town, Grote Schuur, South Africa.
  • Rehal S; MRC Clinical Trials Unit at UCL, London, UK.
  • Kibiki GS; Kilimanjaro Clinical Research Institute, Kilimanjaro Christian Medical Centre, Tumaini University, Moshi, Tanzania.
  • Churchyard G; Aurum Institute, Johannesburg, South Africa; School of Public Health, University of Witwatersrand, Johannesburg, South Africa; Department of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK.
  • Sanne I; Helen Joseph Hospital, Johannesburg, South Africa.
  • Ntinginya NE; National Institute for Medical Research, Mbeya Medical Research Centre, Mbeya, Tanzania.
  • Minja LT; Ifakara Health Institute, Bagamoyo, Tanzania.
  • Hunt RD; Division of Infection and Immunity, Centre for Clinical Microbiology, University College London, UK.
  • Charalambous S; Aurum Institute, Johannesburg, South Africa.
  • Hanekom M; Centre for Clinical Tuberculosis Research, Department of Science and Technology and National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, South Africa.
  • Semvua HH; Kilimanjaro Clinical Research Institute, Kilimanjaro Christian Medical Centre, Tumaini University, Moshi, Tanzania.
  • Mpagama SG; Kibong'oto National Tuberculosis Hospital, Tanzania.
  • Manyama C; National Institute for Medical Research, Mbeya Medical Research Centre, Mbeya, Tanzania.
  • Mtafya B; National Institute for Medical Research, Mbeya Medical Research Centre, Mbeya, Tanzania.
  • Reither K; Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.
  • Wallis RS; Aurum Institute, Johannesburg, South Africa.
  • Venter A; MRC Centre for Tuberculosis Research, University of Stellenbosch, Tygerberg, South Africa.
  • Narunsky K; Centre for Tuberculosis Research Innovation, University of Cape Town, Grote Schuur, South Africa.
  • Mekota A; Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich, Munich, Germany.
  • Henne S; Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich, Munich, Germany.
  • Colbers A; Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands.
  • van Balen GP; Department of Lung Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
  • Gillespie SH; Medical School University of St Andrews, North Haugh, St Andrews, UK.
  • Phillips PPJ; MRC Clinical Trials Unit at UCL, London, UK.
  • Hoelscher M; Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich, Munich, Germany; German Center for Infection Research, Partner Site Munich, Germany.
Lancet Infect Dis ; 17(1): 39-49, 2017 01.
Article in En | MEDLINE | ID: mdl-28100438
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rifampin / Tuberculosis, Pulmonary / Adamantane / Fluoroquinolones / Drug Therapy, Combination / Ethylenediamines / Antitubercular Agents Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies Limits: Adult / Female / Humans / Male Country/Region as subject: Africa Language: En Journal: Lancet Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2017 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rifampin / Tuberculosis, Pulmonary / Adamantane / Fluoroquinolones / Drug Therapy, Combination / Ethylenediamines / Antitubercular Agents Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies Limits: Adult / Female / Humans / Male Country/Region as subject: Africa Language: En Journal: Lancet Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2017 Document type: Article